Systemic inlammatory status at baseline predicts bevacizumab beneit in advanced non-small cell lung cancer patients

Cancer Biology and Therapy

Volumn 14, Issue 6, 2013, Pages 469-475

  Botta, Cirino ^a   Barbieri, Vito ^a   Ciliberto, Domenico ^a   Rossi, Antonio ^b   Rocco, Danilo ^c   Addeo, Rafaele ^d   Staropoli, Nicoletta ^a   Pastina, Pierpaolo ^e   Marvaso, Giulia ^a   Martellucci, Ignazio ^e   Guglielmo, Annamaria ^e   Pirtoli, Luigi ^e   Sperlongano, Pasquale ^f   Gridelli, Cesare ^b   Caraglia, Michele ^f,g   Tassone, Pierfrancesco ^a,g   Tagliaferri, Pierosandro ^a   Correale, Pierpaolo ^e  

^a Department of experimental and Clinical Medicine ^*  (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

^c AORN Vincenzo Monaldi   (Italy)

^d SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^e UNIVERSITY OF SIENA   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

^g Temple University   (United States)

Author keywords

Angiogenesis; Bevacizumab; Inflammation; Lung cancer; Monocytes; Neutrophil to lymphocyte ratio; Neutrophils

Indexed keywords

BEVACIZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL; OVERALL SURVIVAL; PERIPHERAL LYMPHOCYTE; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; IMMUNOLOGY; LUNG NEOPLASMS; LYMPHOCYTE COUNT; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEUTROPHILS; PLATELET COUNT; PLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84879182577     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.24425     Document Type: Article

References (44)

1. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E; ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl 7):vii56-64; PMID:22997455; http://dx.doi.org/10.1093/annonc/mds226.
2. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008; 26:4617-25; PMID:18678835; http://dx.doi.org/10.1200/JCO.2008.17.7162.
3. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a singleagent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004; 292:470-84; PMID:15280345; http://dx.doi.org/10.1001/jama.292.4.470.
4. Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005; 47:69-80; PMID:15603856; http://dx.doi.org/10.1016/j.lungcan.2004.10.014.
5. Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin-and carboplatinbased doublet chemotherapeutic regimens versus nonplatinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008; 59:1-11; PMID:17720276; http://dx.doi.org/10.1016/j.lungcan.2007.07.012.
6. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-51; PMID:18506025; http://dx.doi.org/10.1200/JCO.2007.15.0375.
7. Correale P, Cusi MG, Tagliaferri P. Immunomodulatory properties of anticancer monoclonal antibodies: is the 'magic bullet' still a reliable paradigm? Immunotherapy 2011; 3:1-4; PMID:21174549; http://dx.doi.org/10.2217/ imt.10.92.
8. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50; PMID:17167137; http://dx.doi.org/10.1056/ NEJMoa061884.
9. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-34; PMID:19188680; http://dx.doi.org/10.1200/ JCO.2007.14.5466.
10. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al.; BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21:1804-9; PMID:20150572; http://dx.doi.org/10.1093/annonc/mdq020.
11. Albini A, Tosetti F, Benelli R, Noonan DM. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 2005; 65:10637-41; PMID:16322203; http://dx.doi.org/10.1158/0008-5472.CAN-05-3473.
12. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011; 17:1359-70; PMID:22064426; http://dx.doi.org/10.1038/nm.2537.
13. Vitale G, Dicitore A, Gentilini D, Cavagnini F. Immunomodulatory effects of VEGF: Clinical implications of VEGF-targeted therapy in human cancer. Cancer Biol Ther 2010; 9:694-8; PMID:20339315; http://dx.doi.org/10.4161/cbt.9.9.11691.
14. Ferrara N. Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr Opin Hematol 2010; 17:219-24; PMID:20308892.
15. Gridelli C, Rossi A. Unanswered questions: monoclonal antibodies in the treatment of advanced non-smallcell lung cancer. [Williston Park]. Oncology (Williston Park) 2010; 24:1216-23; PMID:21192561.
16. Mok T, Gorbunova V, Juhasz E, Szima B, Burdaeva O, Yu CJ, et al. 9003 ORAL Biomarker Analysis in BO21015, a Phase II Randomised Study of First-line Bevacizumab (BEV) Combined With Carboplatingemcitabine (CG) or Carboplatin-paclitaxel (CP) in Patients (pts) With Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer (NSCLC). European journal of cancer 2011; 47:S592; http://dx.doi.org/10.1016/S0959-8049(11)72315-2.
17. Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer 2010; 46:1323-32; PMID:20236818; http://dx.doi.org/10. 1016/j.ejca.2010.02.020.
18. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010; 11:1172-83; PMID:21126687; http://dx.doi.org/10.1016/S1470-2045(10)70232-1.
19. Nielsen BS, Timshel S, Kjeldsen L, Sehested M, Pyke C, Borregaard N, et al. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 1996; 65:57-62; PMID:8543396; http://dx.doi.org/10.1002/(SICI)1097- 0215(19960103)65:1;57: :AIDIJC10 3.0.CO;2-F.
20. Mentzel T, Brown LF, Dvorak HF, Kuhnen C, Stiller KJ, Katenkamp D, et al. The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. Virchows Arch 2001; 438:13-22; PMID:11213831; http://dx.doi.org/10.1007/s004280000327.
21. Mhawech-Fauceglia P, Kaya G, Sauter G, McKee T, Donze O, Schwaller J, et al. The source of APRIL upregulation in human solid tumor lesions. J Leukoc Biol 2006; 80:697-704; PMID:16793914; http://dx.doi.org/10.1189/jlb.1105655.
22. Schaider H, Oka M, Bogenrieder T, Nesbit M, Satyamoorthy K, Berking C, et al. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 2003; 103:335-43; PMID:12471616; http://dx.doi.org/10.1002/ijc.10775.
23. Shamamian P, Schwartz JD, Pocock BJ, Monea S, Whiting D, Marcus SG, et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 2001; 189:197-206; PMID:11598905; http://dx.doi.org/10.1002/jcp.10014.
24. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6:409-21; PMID:15488763; http://dx.doi.org/10.1016/j.ccr.2004.08.031.
25. Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A 2006; 103:12493-8; PMID:16891410; http://dx.doi.org/10.1073/pnas. 0601807103.
26. Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A 2009; 106:6742-7; PMID:19346489; http://dx.doi.org/10.1073/pnas.0902280106.
27. Coffelt SB, Tal AO, Scholz A, De Palma M, Patel S, Urbich C, et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 2010; 70:5270-80; PMID:20530679; http://dx.doi.org/10.1158/0008-5472.CAN-10-0012.
28. Coffelt SB, Chen YY, Muthana M, Welford AF, Tal AO, Scholz A, et al. Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. J Immunol 2011; 186:4183-90; PMID:21368233; http://dx.doi.org/10.4049/jimmunol.1002802.
29. Cedrés S, Torrejon D, Martínez A, Martinez P, Navarro A, Zamora E, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol 2012; 14:864-9; PMID:22855161; http://dx.doi.org/10.1007/s12094-012-0872-5.
30. Botta C, Mazzanti R, Guglielmo A, Cusi M, Vincenzi B, Mantovani G, et al. 1439 POSTER Treatmentrelated Changes in Systemic Inflammatory Status, Measured by Neutrophil-to-lymphocyte Ratio, is Predictive of Outcome in Metastatic Colorectal Cancer Patients. Eur J Cancer 2011; 47:S181; http://dx.doi.org/10. 1016/S0959-8049(11)70932-7.
31. Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 2012; 48:202-8; PMID:22018713; http://dx.doi.org/10.1016/j.ejca.2011.09.001.
32. Botta C, Mazzanti R, Cusi M, Vincenzi B, Mantovani G, Licchetta A, et al. 1418 POSTER Baseline Inflammatory Status Defined by Neutrophil to Lymphocyte Cell Count Ratio (NLR) Predicts Progression Free Survival (PFS) in Metastatic Colorectal Cancer Patients (mCRC) Undergoing Bevacizumab Based Biochemotherapy. Eur J Cancer 2011; 47:S174-5; http://dx.doi.org/10.1016/S0959-8049(11)70911-X.
33. Yao Y, Yuan D, Liu H, Gu X, Song Y. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced nonsmall cell lung cancer patients treated with firstline platinum-based chemotherapy. Cancer Immunol Immunother 2013; 62:471-9; PMID:22986452; http://dx.doi.org/10. 1007/s00262-012-1347-9.
34. Lissoni P, Brivio F, Fumagalli L, Messina G, Ghezzi V, Frontini L, et al. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers 2004; 19:135-40; PMID:15255546.
35. Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, et al. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res 2008; 14:4192-9; PMID:18593999; http://dx.doi.org/10.1158/1078-0432.CCR-07-5278.
36. Botta C, Bestoso E, Apollinari S, Cusi MG, Pastina P, Abbruzzese A, et al. Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients. J Immunother 2012; 35:440-7; PMID:22576349; http://dx.doi.org/10.1097/CJI.0b013e31825943aa.
37. Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginanneschi C, et al. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 2010; 33:435-41; PMID:20386463; http://dx.doi.org/10.1097/CJI.0b013e3181d32f01.
38. Correale P, Rotundo MS, Botta C, Del Vecchio MT, Tassone P, Tagliaferri P. Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer. Oncoimmunology 2012; 1:531-2; PMID:22754775; http://dx.doi.org/10.4161/onci.19404.
39. Correale P, Rotundo MS, Botta C, Del Vecchio MT, Ginanneschi C, Licchetta A, et al. Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. Clin Cancer Res 2012; 18:850-7; PMID:22142823; http://dx.doi.org/10. 1158/1078-0432.CCR-10-3186.
40. Vitale G, Abbruzzese A, Tonini G, Santini D. Chemo-immunotherapy: a new option for non-small cell lung cancer. Cancer Biol Ther 2009; 8:503-4; PMID:19242127; http://dx.doi.org/10.4161/cbt.8.6.7770.
41. Correale P, Tindara Miano S, Remondo C, Migali C, Saveria Rotundo M, Macrì P, et al. Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. Cancer Biol Ther 2009; 8:497-502; PMID:19242101; http://dx.doi.org/10.4161/cbt.8.6.7593.
42. Correale P, Botta C, Basile A, Pagliuchi M, Licchetta A, Martellucci I, et al. Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-celllung cancer patients. Cancer Biol Ther 2011; 12:112-8; PMID:21525780; http://dx.doi.org/10. 4161/cbt.12.2.15722.
43. Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, et al. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. Cancer Biol Ther 2010; 9:685-93; PMID:20697196; http://dx.doi.org/10.4161/cbt.9.9.11441.
44. Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010; 11:733-40; PMID:20650686; http://dx.doi.org/10.1016/S1470-2045(10) 70151-0.